US and EU filings for Astellas' first-in-class OAB drug mirabegron
This article was originally published in Scrip
Astellas has filed for the approval of its first-in-class beta-3 adrenoceptor agonist mirabegron in the US and EU markets for the treatment of overactive bladder (OAB), in line with the company's guidance that it would do so by the end of the fiscal second quarter on 30 September.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.